Ocular Therapeutix Showcases Innovations at Upcoming Retina Events
![Ocular Therapeutix Showcases Innovations at Upcoming Retina Events](https://investorshangout.com/images/blog/ihnews-Ocular%20Therapeutix%20Showcases%20Innovations%20at%20Upcoming%20Retina%20Events.jpg)
Ocular Therapeutix Advances Vision Therapy
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company dedicated to enhancing vision through innovative treatments for eye diseases, recently announced significant participation at several renowned retina meetings scheduled in September. These events will be held in prominent locations, showcasing groundbreaking advancements in retinal therapies.
Key Presentations Announced
As part of their commitment to improving vision health, Ocular Therapeutix is set to present critical findings during various sessions at the upcoming retina meetings. This includes the prestigious Retina Society's 57th Annual Scientific Meeting slated for September 11-15 in Lisbon. This meeting is a significant gathering for ophthalmic experts to discuss the latest research and therapeutic approaches in retinal diseases.
Significant Sessions and Presentations
One of the notable presentations during the Retina Society meeting is titled 52-week Rescue-Free Subjects Treated with Axitinib Hydrogel Implant (OTX-TKI) in the US Phase 1 Clinical Trial for Neovascular Age-Related Macular Degeneration. This session is scheduled for September 13, where Dr. Andrew A. Moshfeghi will lead the discussion.
Another important presentation, focusing on the Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR, will reveal one-year results from the HELIOS Phase 1 Trial. Dr. Dennis M. Marcus will present these findings on September 14.
Additional Engagements at the Ophthalmology Futures Forums
Following the Retina Society meeting, Ocular Therapeutix will also participate in the Ophthalmology Futures Forums 2024 on September 18 in Barcelona. Key highlights include a panel discussion led by Dr. Nadia K. Waheed, addressing Tyrosine Kinase Inhibitors and Other Novel Mechanisms for the Treatment of Neovascular AMD. Dr. Peter K. Kaiser will also share insights on novel drug delivery approaches for posterior segment diseases.
Spotlight on EURETINA Congress
Moreover, the 24th EURETINA Congress from September 19-22 will feature Ocular Therapeutix prominently. Notably, Dr. Veeral S. Sheth will present the 48-Week Safety and Efficacy Results from the Phase 1 HELIOS trial of Sustained-Release Axitinib Implant (OTX-TKI) for Non-Proliferative Diabetic Retinopathy on September 20.
As part of their commitment to providing insightful data, an audio presentation on a Phase 1 Clinical Trial will be available, showcasing findings on the sustained-release Axitinib Hydrogel Implant for Neovascular Age-Related Macular Degeneration.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. stands at the forefront of biopharmaceutical innovation aimed at enhancing vision. Their flagship product, AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), is vital in treating retinal diseases, particularly wet age-related macular degeneration (wet AMD). Currently, it is advancing through Phase 3 clinical trials, demonstrating Ocular's dedication to redefining therapeutic options for patients.
In addition to AXPAXLI, Ocular’s diverse pipeline utilizes the proprietary ELUTYX™ technology, underpinning products like DEXTENZA, an FDA-approved corticosteroid for post-operative ocular inflammation. Their continuous research and clinical efforts also include the PAXTRAVA™ implant which targets open-angle glaucoma.
Stay Connected with Ocular Therapeutix
The commitment to innovation by Ocular Therapeutix is evident in their active participation in leading scientific forums. For further information on their projects and progress, stakeholders and interested parties can connect with the company through their official website and social media channels.
For any inquiries, Ocular Therapeutix's Vice President of Investor Relations, Bill Slattery, is available at bslattery@ocutx.com.
Frequently Asked Questions
What is the primary focus of Ocular Therapeutix?
Ocular Therapeutix focuses on the development of innovative therapies to improve vision and treat retinal diseases.
Where are the upcoming presentations taking place?
The presentations are scheduled at major retina meetings in Portugal and Spain during September.
What is AXPAXLI?
AXPAXLI is an axitinib intravitreal implant designed for treating retinal diseases, currently in Phase 3 trials for wet AMD.
Who are the key speakers for Ocular Therapeutix's presentations?
Notable presenters include Dr. Andrew A. Moshfeghi, Dr. Dennis M. Marcus, and Dr. Nadia K. Waheed.
How can I learn more about Ocular Therapeutix?
You can learn more by visiting Ocular Therapeutix's website or by contacting their investor relations team.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Unlocking Profitable Investment Strategies for Success
- Axoni Achieves Prestigious Award for Operational Risk Excellence
- White Lodging Achieves High Ranking in Guest Satisfaction
- Surge in Automotive Telematics Market Fuels Innovation and Growth
- BRG Welcomes Investment Arbitration Expert Michael Seelhof
- Eclipse Corporation Launches Testing for Revolutionary DocOrigin Cloud
- Navigating the Surge in Data Center Demand and Investments
- Govee Launches Groundbreaking Smart Lighting Products at IFA 2024
- Investigation into Better Choice Company Inc. by Ademi LLP
- Nichad Davis Honored Again as National Black Lawyer's Top 40 Under 40
Recent Articles
- Understanding the Impact of Stock Splits on Tech Stocks
- Exploring Roth Contributions for Retirement Planning in Your 50s
- Unlocking Profitable Investment Strategies for Success
- Discovering Environmental Stories in the Rural South
- Services Sector Shows Modest Growth Amid Economic Pressures
- Axoni Achieves Prestigious Award for Operational Risk Excellence
- White Lodging Achieves High Ranking in Guest Satisfaction
- Understanding Insurance Fraud: Charges and Legal Consequences
- Surge in Automotive Telematics Market Fuels Innovation and Growth
- BRG Welcomes Investment Arbitration Expert Michael Seelhof
- The Future of Baby Diapers: A Market Set for Expansion
- Eclipse Corporation Launches Testing for Revolutionary DocOrigin Cloud
- Uphold Launches FDIC-Insured USD Interest Accounts with High APY
- Navigating the Surge in Data Center Demand and Investments
- Govee Launches Groundbreaking Smart Lighting Products at IFA 2024
- Nokia Shines as Leader in 2024 Gartner Magic Quadrant for 5G
- Crafting a Future: The Transforming Beer Market Landscape
- Exploring the Surge: Streaming Analytics Market Growth Ahead
- Investigation into Better Choice Company Inc. by Ademi LLP
- Top U.S. Cities for Young Veterans Seeking Affordable Homes
- Nichad Davis Honored Again as National Black Lawyer's Top 40 Under 40
- Is CrossFirst Bankshares Getting a Fair Deal? An Investigation
- Subaru Achieves Highest Satisfaction Scores in Recent Survey
- Transforming Communication: ZTE and Orange Liberia Unite
- FASTSIGNS Achieves Record Attendance at Annual Sales Summit
- Join Investors and Companies at Benzinga's SmallCap Conference
- Investigation Launched on Fair Price for Frontier Communications
- 3M Xtract Cubitron II Film Disc 775L: A Decade of Innovation
- Ghana's Strategic Move: Restructuring $13 Billion in Bonds
- Citi Analysts Predict Major Margin Gains for Intel
- Utz Brands Adjusts Financial Forecast Amid Market Changes
- Applied Digital's Stock Soars After Major Funding Announcement
- Navigating the Recent US Stock Market Trends and Insights
- Insight into Baltic Horizon Fund's Sustainability Practices
- Baltic Horizon Fund's Commitment to Sustainable Investing
- Powell Max Limited Sets Price for Initial Share Offering
- Colts Enhance Performance with New Matrix Helix Turf Upgrade
- Innovative Eco-Friendly Writing Solutions from Tom's Studio
- Transforming Pediatric Mental Health Care with CBT Scholarships
- Xiao-I Corporation Expects 25% Revenue Growth in 2024
- Celebrating Global Impact: HHRD's Charitable Outreach Initiative
- Lincoln the Lawyer Unveils Debut Album 'Interludes'
- Endeavor 3D Secures ITAR Status to Boost Defense Manufacturing
- Celebrating a Legacy: Mom's Meals Takes a Stand Against Hunger
- ams OSRAM and LEDVANCE Forge a Bright Future Together
- Orange Liberia and ZTE Enhance Rural Connectivity with New Sites
- Exciting Highlights of the 11th Annual NoHo CineFest Adventure
- Market Patterns Shift: The Emerging Importance of Bonds
- Cybersecurity Budgets See Modest Growth Amid Economic Challenges
- Dollar Tree Faces Analyst Downgrades Amid Uncertainty